Related Experiment Video
Updated: Mar 9, 2026
A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
Published on: June 22, 2022
Matrix Metalloproteinase-9 and Recovery of Acute Ischemic Stroke
Maged M Abdelnaseer1, Nervana M Elfauomy1, Eman H Esmail1
1Neurology Department, Cairo University, Giza, Egypt.
Background:
Stroke outcome can be predicted by clinical features, biochemical parameters, and some risk factors. Matrix metalloproteinase-9 (MMP-9) is involved in various stages of stroke pathology. MMP-9 inhibitors are potential stroke therapeutic agents. Little is known about the relation between MMP-9-after the acute stage-and clinical recovery.
Objective:
The study aimed to investigate the serum level of MMP-9 at stroke onset as predictor of stroke outcome and the relation between the level of MMP-9 after 30 days and stroke recovery.
Methods:
The National Institutes of Health Stroke Scale, modified Rankin Scale, and serum level of MMP-9 were assessed in 30 patients with acute ischemic stroke during the first 24 hours of onset and then a month later. None of the patients received thrombolytic therapy. Thirty normal volunteers of matched age and sex were included in the control group.
Results:
The serum level of MMP-9 at stroke onset was independently positively correlated with stroke outcome. The serum level of MMP-9 30 days after stroke onset was positively correlated with initial stroke severity and outcome, as well as with clinical recovery.
Conclusion:
Higher serum level of MMP-9 at stroke onset can be a predictor of poor stroke outcome. However, beyond the acute stage, MMP-9 may play beneficial role in stroke recovery.
Insights
Elevated matrix metalloproteinase-9 (MMP-9) at stroke onset predicts poor outcomes. However, MMP-9 may aid clinical recovery after the acute phase, suggesting a dual role in stroke pathology.
Area of Science:
- Biochemistry
- Neurology
- Stroke Research
Background:
- Stroke outcome is influenced by clinical factors and biomarkers.
- Matrix metalloproteinase-9 (MMP-9) plays a role in stroke pathology.
- The role of MMP-9 in post-acute stroke recovery is not well understood.
Purpose of the Study:
- To determine if serum MMP-9 levels at stroke onset predict stroke outcome.
- To investigate the relationship between MMP-9 levels after 30 days and stroke recovery.
Main Methods:
- Assessed National Institutes of Health Stroke Scale, modified Rankin Scale, and serum MMP-9 in 30 acute ischemic stroke patients within 24 hours and 30 days.
- No patients received thrombolytic therapy.
- Included 30 age- and sex-matched healthy volunteers as controls.
Main Results:
- Serum MMP-9 levels at stroke onset positively correlated with stroke outcome.
- Serum MMP-9 levels at 30 days post-stroke correlated with initial stroke severity, outcome, and clinical recovery.
Conclusions:
- Higher serum MMP-9 at stroke onset predicts poor stroke outcomes.
- MMP-9 may have a beneficial role in stroke recovery beyond the acute stage.
